Thursday, September 3, 2026
← Back to archivePolicy
Policy•STAT News•Sep 2, 2026
Doctors groups release vaccination guidelines ahead of respiratory illness season
background ▾
- •Professional medical societies have bypassed the CDC to issue independent vaccination guidance due to ACIP's dismantlement and replacement with vaccine skeptics, marking a significant rupture in established immunization policy-setting infrastructure
- •ACOG has extended RSV vaccine eligibility for pregnant people from January 31 to March 1, reflecting evolving epidemiologic patterns of RSV seasonality
- •Legal challenges to ACIP's restructuring leave vaccination recommendations in limbo; monitor court outcomes and potential reinstatement of original advisory committee structure, which could affect policy consistency and provider compliance
influenza vaccineCovid-19 vaccineRSV vaccine
→ Read original articlePolicy•STAT News•Sep 3, 2026
Opinion: STAT+: A surprising bright spot at the FDA on regulating unproven stem cells
background ▾
- •The FDA has maintained science-based regulatory enforcement against unproven stem cell clinics despite political pressure and the HHS Secretary's personal endorsement of unapproved treatments
- •The scale of the problem is substantial, with an estimated 2,000+ unproven stem cell firms operating across the U.S. selling non-FDA-approved cellular products
- •Monitor FDA enforcement actions and policy statements on stem cell regulation for concrete details on the specific regulatory successes referenced
Policy•STAT News•Sep 3, 2026
Opinion: I was a doula before I was an OB-GYN. I wish the two professions understood each other more
background ▾
Policy•STAT News•Sep 3, 2026
The pediatricians who take in vaccine-skeptical parents others won’t
background ▾
- •The Trump administration has altered federal childhood vaccine recommendations by reducing the number of recommended vaccines and ordering the MMR vaccine be administered as three separate shots rather than combined, reversing long-standing CDC/AAP guidance and creating confusion among families and providers.
MMR (measles, mumps, rubella) vaccine
→ Read original articlePolicy•STAT News•Sep 3, 2026
Why are drug overdose deaths declining?
background ▾
- •U.S. overdose deaths fell 27% in 2024 after years of 100,000+ annual deaths, with similar trends in Canada (9%) and Scotland (13%), representing an epidemiologically unprecedented decline
- •Multiple public health interventions appear responsible: naloxone distribution requirements, Medicaid expansion enabling medication access, and in-prison treatment programs—with Virginia achieving 40% reduction and Maryland 25% reduction
- •Critical uncertainty remains regarding sustainability given pending Medicaid cuts and Trump administration opposition to certain harm reduction strategies despite support for opioid use disorder medications
naloxonemethadonebuprenorphine
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 2, 2026
Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division
background ▾
- •Fortrea expands early-phase CRO capacity with acquisition of Worldwide's clinical pharmacology and bioanalytical operations, addressing a critical bottleneck in its phase 1-2 platform.
- •The deal includes significant physical infrastructure (60,000-sq-ft GLP lab, 200-bed clinical unit in Texas) that immediately adds trial execution capacity and reduces operational handoffs.
- •Watch for: whether this acquisition translates to tangible improvements in trial timeline efficiency and customer retention, especially given Fortrea's recent operational challenges including the Acelyrin phase 3 dosing error incident.
FortreaWorldwide Clinical TrialsLabcorp
→ Read original articleMarket Access•Endpoints News•Sep 3, 2026
GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
background ▾
- •GSK's $110M upfront plus $1.185B milestone structure signals confidence in the KRAS-EGFR conjugate's commercial potential and differentiation in a crowded KRAS inhibitor landscape
- •The deal reflects ongoing pharma investment in dual-targeted mechanisms addressing both KRAS and EGFR signaling, positioning the asset as potentially distinct from monovalent KRAS G12C inhibitors
- •Monitor clinical trial progression, regulatory feedback on the dual-targeting mechanism, and competitive positioning versus approved KRAS inhibitors and other combination approaches in solid tumors
GSKHutchmedKRAS-EGFR antibody-drug conjugate
→ Read original articleMarket Access•Fierce Biotech•Sep 2, 2026
Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen
background ▾
- •Novartis gains multiple exclusive options to develop drugs using Alteogen's ALT-B4 subcutaneous delivery technology, potentially covering several therapeutic programs with up to $3.2B in total value
- •Alteogen has rapidly consolidated market leadership in subcutaneous delivery, now partnering with Novartis, Biogen, GSK, AstraZeneca, and Merck—establishing credible competition against established player Halozyme
- •Watch for: Which Novartis programs Alteogen technology will be applied to, exercise of options by Novartis, and whether subcutaneous formulation becomes standard for future Novartis biologics launches
NovartisAlteogenBiogenKeytruda
→ Read original articleMarket Access•Endpoints News•Sep 2, 2026
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies
background ▾
- •Typewriter secured $56M to develop transposon-based gene delivery and in vivo CAR-T therapies, representing investor confidence in non-viral gene delivery platforms
- •The technology aims to address limitations of viral vector-based approaches by using naturally occurring jumping genes for therapeutic gene insertion
Typewriter
→ Read original articleClinical Trials
Clinical Trials•Endpoints News•Sep 3, 2026
Superluminal secures $60M for Phase 1 of genetic obesity drug
background ▾
- •Superluminal has $60M to advance MC4R-targeting obesity therapy into Phase 1 human testing
- •The MC4R obesity drug class remains competitive with other players like Rhythm Pharmaceuticals already in development or approved
SuperluminalRhythm Pharmaceuticals
→ Read original articleClinical Trials•Endpoints News•Sep 3, 2026
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patients
background ▾
- •Ultragenyx's Phase 3 trial for an Angelman syndrome therapy failed primary endpoints, a major clinical development for a rare disease with limited treatment options
- •The setback impacts both the company's pipeline and the patient population with limited approved therapies for this neurodevelopmental condition
- •Clarity needed on trial results, whether Ultragenyx will pursue alternative approaches, and how this affects the competitive landscape for Angelman syndrome programs in development
Ultragenyx
→ Read original articleClinical Trials•Endpoints News•Sep 2, 2026
Novartis CAR-T deaths raise questions over acceptable autoimmune risk
background ▾
- •Three patient deaths in Novartis' autoimmune-indication CAR-T trial have triggered industry-wide discussion about risk acceptability for non-oncology applications where patients are not facing terminal illness
- •The incident raises questions about how regulators will establish safety benchmarks for CAR-T therapies in chronic autoimmune diseases versus their well-established but still-dangerous oncology profile
- •Watch for regulatory guidance on CAR-T safety requirements in autoimmune indications and how other sponsors adjust clinical trial designs and endpoints for similar programs
NovartisCAR-T cell therapy
→ Read original articleClinical Trials•Endpoints News•Sep 2, 2026
Teva says gluten challenge study succeeds in celiac disease
background ▾
- •Single-injection anti-body therapy achieved significant intestinal protection during gluten challenge in celiac disease patients, demonstrating proof-of-concept for a mechanistic approach to the disease
- •This marks a clinically meaningful result in an underserved indication where dietary restriction is the only established management; positive efficacy could reshape treatment paradigms if confirmed in late-stage trials
- •Monitor for Phase 3 initiation timeline, regulatory interactions with FDA/EMA on trial design, and competitive developments from other celiac disease candidates (e.g., Landsteiner Scientific, ImmusanT)
Teva Pharmaceuticals<antibody therapy (INN not disclosed in article)>
→ Read original articleClinical Trials•Fierce Biotech•Sep 2, 2026
TScan axes 75% of workforce to make room for solid tumor programs
background ▾
- •TScan is pausing phase 1 (Alloha) and phase 3 (Alloha-2) trials for TSC-101 in AML/MDS despite early phase 1 data showing 12/14 patients without relapse at six months, seeking external partnerships to complete development.
- •The strategic pivot to in vivo-engineered TCR-T therapies for solid tumors (PRAME, MAGE-A4) represents a fundamental business model shift away from autologous cell therapies, addressing manufacturing and cost challenges.
- •Watch for: (1) partnership announcements for hematological and autoimmunity programs; (2) phase 1 initiation timelines for solid tumor candidates; (3) competitive positioning relative to other TCR-T developers in solid tumors; (4) additional capital raises or further restructuring if partnerships fail to materialize.
TScan TherapeuticsAmgenArsenalBioTSC-101PRAMEMAGE-A4
→ Read original article